MedDataX Logo

Treatment of Neuroleptic Induced Acute Akathisia With Trazodone

NCT00659919 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2008-06-17

No results posted yet for this study

Summary

Administration of trazodone for the treatment of neuroleptic induced acute akathisia in a cross-over fashion of 6 days duration. 3 days of placebo and 3 days of trazodone.

Conditions

  • Schizophrenia

Interventions

DRUG

Placebo

DRUG

Trazodone

Sponsors & Collaborators

  • BeerYaakov Mental Health Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-11-30
Primary Completion
2003-12-31
Completion
2003-12-31

Countries

  • Israel

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00659919 on ClinicalTrials.gov